Focusing on the Diabetes Patient

Published Online: Friday, November 8, 2013
Follow Pharmacy_Times:
Jonathan G. Marquess, PharmD, CDE, President and CEO of the Institute for Wellness and Education, Inc, explains why he decided to focus on caring for diabetes patients at his pharmacy. This interview was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.

Related Articles
The FDA has approved the intravitreal implant, Iluvien 0.19 mg, as the first long-term treatment for diabetic macular edema.
Pharmacists who participate in community-based diabetes care teams play a pivotal role in reducing A1C levels among patients with poorly controlled diabetes.
The dexamethasone intravitreal implant, Ozurdex, is now indicated to treat all patients with diabetic macular edema.
The FDA has cleared the Nova StatStrip Glucose Hospital Meter System to become the first blood glucose monitoring system for use in critically ill patients who have been hospitalized.
Latest Issues
$auto_registration$